A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Key Inclusion Criteria:
Diagnosis of diabetes mellitus type 1 or type 2 with
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
medicalinfo@vrtx.com617-341-6777
Wheat Ridge, Colorado 80033, United States
Moncks Corner, South Carolina 29461, United States
Clermont-Ferrand, France
Offenbach/Main, Germany
Birmingham, United Kingdom